Funded Local Who is raising money in your own backyard?

Vancouver, British Columbia – September 3, 2009 – Lignol Energy Corporation (TSX-V: LEC) ("Lignol" or "the Company"), a leading technology company in the cellulosic ethanol and biorefining sector, today announced that a project led by its wholly-owned subsidiary, Lignol Innovations Ltd., has been awarded up to $1.18 million in funding assistance from BC Bioenergy Network Association ("BCBN"). With this contribution, BCBN will provide funding to Lignol to work with several British Columbia Universities to support mission-driven lignin research for commercial applications.

Vancouver, BC – August 31, 2009 – Nexterra Systems Corp. (www.nexterra.ca) a leading supplier of advanced biomass gasification systems announced today it has received $7.7M in funding from the BC Bioenergy Network (BCBN), Sustainable Development Technology Canada (SDTC), the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP), and Ethanol BC.

Vancouver, Canada, August 25, 2009 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) (“Cardiome” or the “Company”) announced today that its Board of Directors has authorized management to proceed with a tender offer to purchase for cancellation up to 6,470,588 of its common shares for an aggregate purchase price of up to US$27.5 million. The offer will be conducted as a modified “Dutch auction”, which will enable shareholders to select a price between US$4.25 per share and US$5.10 per share at which they are willing to tender their common shares to the offer.

VANCOUVER, BC – August 10, 2009 – IP Applications Corp. (TSX-Venture: IPX) ("IP Applications" or the "Company") is pleased to announce that, further to the Company’s news release of May 26, 2009, it has formally closed its non-brokered private placement and raised gross proceeds of $1,000,000.

VANCOUVER, Jul 24, 2009 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has completed its registered direct offering, previously announced on July 20, 2009, of 475,000 shares of its common stock to institutional investors at a price of $20.00 per share, for gross proceeds to the Company of approximately $9.5 million. The $20 offering price represented a 3.5% discount to the closing price on July 17, 2009, the last trading day prior to announcement.

VANCOUVER, Jul 20, 2009 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today it has entered into purchase agreements with certain institutional investors for the sale of 475,000 shares of its common stock at a price of $20 per share through a registered direct offering. The transaction is expected to provide gross proceeds of $9.5 million to OncoGenex before deducting costs associated with the offering, and will be used primarily for manufacturing activities and general corporate purposes.

Vancouver, BC - Lat49, the leading network in geo-contextual advertising, today announced that the company has closed a $1.5 million Series A financing led by PenderFund Capital Management (Pender), with participation from existing investors including Discovery Capital.

VANCOUVER: Avcorp Industries Inc. (“Avcorp”) (TSX: AVP) announced today that it has entered into an amended transaction with Panta Holdings B.V. (“Panta”). Avcorp and Panta have amended their Investment Agreement dated June 15, 2009, the original terms of which did not receive the approval of the Toronto Stock Exchange (“TSX”). Under the amended agreement, Panta has agreed to purchase 16,157,465 common shares of Avcorp at a price of C$0.15 per share for a total gross proceeds of C$2,423,620 (the “Panta Private Placement”).

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held computational biotechnology company, today announced the close of a financing totaling $3.5 million. The financing included an institutional investment by CTI Life Sciences Fund (“CTI”) and the completion of its existing private financing round. Further financial terms are not disclosed. Zymeworks will use the proceeds to fund ongoing validation and research programs leading to the advancement of Zymeworks’ protein therapeutics pipeline.

Vancouver, British Columbia, June 18, 2009 — Burcon NutraScience Corporation (TSX –BU) (“Burcon” or the “Corporation”) is pleased to announce that it has completed its previously announced financing led by Paradigm Capital Inc., and including BMO Capital Markets and Haywood Securities Inc. (collectively, the “Agents”).